Pars plana vitrectomy versus three intravitreal injections of bevacizumab for nontractional XXXX . A prospective, randomized comparative study.

@entity1 @entity32 @entity231 @entity548 @entity1713 @entity2286 @entity1103 @entity3225
BACKGROUND: The aim of this study was to compare the effectiveness of pars plana vitrectomy ( @entity2286 ) and removal of the internal limiting membrane (ILM) with three, monthly, intravitreal bevacizumab (IVB) injections for refractory @entity1103 . MATERIALS AND METHODS: This was a prospective, randomized, comparative, interventional study. Forty-four @entity1 were enrolled and randomized in two groups. Twenty-two eyes enrolled in Group I received three IVB injections at monthly interval. Twenty-two eyes were enrolled in Group II which underwent @entity2286 with ILM removal. The primary outcomes measured were: (1) Best corrected logMAR visual acuity (BCVA) using Snellen's visual acuity chart. (2) Central macular thickness (CMT) on optical coherence tomography. The secondary outcome measures were: Complication rates like (1) progression of @entity231 , (2) high intraocular pressure needing further treatment/procedure, (3) development of @entity548 related to the procedure employed, (4) @entity1713 and (5) severe @entity32 / @entity3225 . RESULTS: In Group I (IVB): 3 (13.6%) eyes showed no change in BCVA; 3 (13.6%) eyes reported decrease in BCVA and 16 (72.8%) eyes showed improvement in BCVA; (P = 0.0181). In Group II ( @entity2286 ): 4 (18.2%) eyes showed no change in BCVA; 5 (22.7%) eyes showed decrease and 13 (59.1%) eyes showed improvement in BCVA (P = 0.0281). Mean decrease in CMT in IVB group was 108.45  , whereas mean decrease in CMT in @entity2286 group was 161.36  . No major complications were seen in either group. CONCLUSION: Posttreatment decrease in CMT was more in @entity2286 group and vision improvement more in IVB group. However, no statistically significant difference between the two methods was found.
